Making the connection: gut dysbiosis, allergy and synbiotics

Making the connection: gut dysbiosis, allergy and synbiotics

A deeper understanding of the essential role of the gut microbiome – the community of bacteria that inhabit the gut – in health and disease is changing how we think about cows’ milk protein allergy (CMPA).

Immunity and gut dysbiosis Icon | Paediatrics Healthcare

Immunity and gut dysbiosis

70–80% of immune cells reside in the gut.1 A balanced gut microbiota is associated with a healthy immune system that protects against pathogens and provides tolerance to potential allergens.2–4
Gut dysbiosis and CMPA | Paediatrics Healthcare

Gut dysbiosis and CMPA

Infants with CMPA tend to have lower levels of beneficial bacteria and higher levels of harmful bacteria in their gut microbiota compared with healthy, breast-fed infants.5–8 This imbalance in gut microbiota (gut dysbiosis) is linked to an increased risk of allergies and infections in early life.9–11
CMPA and synbiotics | Paediatrics Healthcare

CMPA and synbiotics

The focus of CMPA management has shifted from allergen avoidance to supporting healthy immune response via modulation of the gut microbiota.12 Addition of synbiotics – a synergistic combination of pre- and probiotics – to infant formula has shown to help rebalance the gut microbiota and support immune system development.8,13,14

Useful Resources

View all our latest articles
Clinical benefits of SYNEO™ | Paediatrics Healthcare

Clinical benefits of SYNEO™

SYNEO™ is the only CMPA range to contain a unique, patented blend of pre- and probiotics, inspired by components of breast milk, that work together to help promote a healthy gut microbiota and support immune system development.14–17

In clinical trials involving infants with CMPA, addition of SYNEO™ demonstrated:13–16,18,19

Rebalancing of the gut microbiota closer to healthy breastfed infants
Fewer reports of infections and antibiotic use
Fewer reports of asthma-like symptoms and need for asthma medicine after 1 year

Discover how the SYNEO™ range could make a difference to your patients with CMPA

Neocate Syneo
Neocate® SYNEO™
A nutritionally complete, amino acid based, powdered infant formula for special dietary use, with a unique blend of ingredients including short- and long-chain FOS (fructo-oligosaccharides) and Bifidobacterium breve M16V. Available on PBS.
Aptamil® AllerPro Syneo™ - From Birth to 6 Months | Paediatrics Healthcare
Aptamil® AllerPro SYNEO™ Infant Formula (0-6 months)
A nutritionally complete, premium extensively hydrolysed formula (eHF) for infants from birth (0–6 months) with confirmed mild to moderate cows’ milk (not anaphylaxis) and/or soy protein allergy, requiring a partial or complete breast milk substitute.
Aptamil AllerPro Syneo 2 - Follow-On Formula | Paediatrics Healthcare
Aptamil® AllerPro SYNEO™ 2 (6-12 months)
A premium extensively hydrolysed formula (eHF) for infants with confirmed mild to moderate cows’ milk (not anaphylaxis) and/or soy protein allergy, requiring a partial or complete breast milk substitute as part of a mixed diet.

References:

1. Vighi G et al. Clin Exp Immunol. 2008;153(Suppl 1):3–6.
2. Azad M et al. Clin Exp Allergy 2015;45:632–43.
3. Kirjavainen P et al. Gut 2002;51:51–5.
4. Mitsuoka T. Biosci Microbiota Food Health 2014;33:99–116.
5. Roger LC et al. Microbiology 2010;156:3329–41.
6. Abrahamsson TR et al. J Allergy Clin Immunol 2012;129:434–40.
7. Harvey BM et al. Pediatr Res 2014;75:343–51.
8. Candy DCA et al. Pediatr Res 2018;83:677–86.
9. West CE et al. J Allergy Clin lmmunol 2015;135:3–1.
10. Kim BJ et al. Allergy Asthma lmmunol Res 2014;6:389–400.
11. Azad MD et al. BJOG 2016;123:983-93.
12. Sackesen C et al. Front Pediatr 2019;7:372.
13. Van der Aa LB et al. Clin Exp Allergy 2010;40:795–804.
14. Fox AT et al. Clin Transl Allergy 2019;9:5.
15. Jeurink PV et al. Benef Microbes 2013;4:17–30.
16. Scholtens PAMJ et al. J. Annu Rev Food Sci Technol 2012;3:425–447.
17. Martin R et al. Benef Microbes 2010;1(4)367–82.
18. Burks A et al. Pediatr Allergy lmmunol 2015;26:316-22.
19. Chatchatee P et al. J Allergy Clin Immunol 2021; doi; 10.1016/j.jaci.2021.06.025 [Epub ahead of print].